Table 1.
Summary characteristics of the five short-term, placebo-controlled studies of vortioxetine in patients with MDD included in the meta-analyses.
| NCT identifier | Treatment period (weeks) | Dose(s) of vortioxetine tested (mg/day)a | Key inclusion criteria for MDD | Literature citation |
|---|---|---|---|---|
| NCT00839423 | 6 | 5 or 10 | Between 18 and 65 years MADRS total score ⩾30 |
Alvarez et al. 2012 |
| NCT00635219 | 8 | 2.5, 5 or 10 | Between 18 and 75 years MADRS total score ⩾26 |
Baldwin et al. 2012b |
| NCT00735709 | 8 | 1,5 or 10 | Between 18 and 75 years MADRS total score ⩾26 |
Henigsberg et al. 2012 |
| NCT00672958 | 6 | 5 | Between 18 and 75 years MADRS total score ⩾30 |
Jain et al. 2013 |
| NCT00672620 | 8 | 2.5 or 5 | Between 18 and 75 years MADRS total score ⩾22 |
Mahableshwarkar et al. 2013 |
a
For the post hoc meta-analyses, only the 5 and 10 mg doses, approved as per current prescribing information, were included.